AzTrials
AzTrials

Primary Open Angle GlaucomaCOMPASS XXTNCT04629521

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

A study testing CyPass Micro-Stent and Cataract Surgery in people with Primary Open Angle Glaucoma and Cataract, run by Alcon Research at 12 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to assess long-term (10 years post-CyPass implantation) status of the corneal endothelium in subjects who were implanted with the CyPass Micro-Stent in the COMPASS trial. Read more about this study

Who is it for?
Ages 45 years and older
Conditions the study is for
Primary Open Angle Glaucoma, Cataract
What is being tested?
CyPass Micro-Stent and Cataract Surgery
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
12 sitesUnited States
Study dates
21 Dec 2020to 5 Apr 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Implantation with a CyPass Micro-Stent as a participant in the COMPASS trial (NCT01085357) (Transcend Medical, Incorporated, Study Number TMI-09-01).
  • Able to understand the requirements of the study and willing to follow study instructions, provide written informed consent, and agree to comply with all study requirements, including the required study follow-up visits.
  • Other protocol-defined inclusion criteria may apply.

Who cannot join

  • Inability to comply with the protocol or required follow-up visit/procedures.
  • Other protocol-defined exclusion criteria may apply.

Trial locations and contacts

12 sites in 1 country.

12 sites in 1 country

United States12 sites
  • Cape Coral Eye Center

    Cape Coral, Florida, 33904

  • Cincinnati Eye Institute

    Cincinnati, Ohio, 45242

  • Eye Center of Northern Colorado, PC

    Fort Collins, Colorado, 80528

  • Ophthalmology Associates

    Fort Worth, Texas, 76102

  • Eye Physicians and Surgeons of Arizona

    Glendale, Arizona, 85306

  • University Eye Specialists

    Maryville, Tennessee, 37803

  • The Vanderbilt Eye Institute

    Nashville, Tennessee, 37232

  • Coastal Vision Medical Group

    Orange, California, 92868

  • Jones Eye Center PC

    Sioux City, Iowa, 51104

  • Ophthalmology Associates

    St Louis, Missouri, 63131

  • Eye Associates and SurgiCenter of Vineland

    Vineland, New Jersey, 08361

  • Associates In Ophthalmology Ltd.

    West Mifflin, Pennsylvania, 15122

Other trials in United States

About this study

Official title: An Observational Multicenter Clinical Study to Provide Additional Long-Term Follow-up Beyond 60 Months for Subjects Implanted With a CyPass Micro-Stent in the COMPASS Trial

The purpose of this study is to assess long-term (10 years post-CyPass implantation) status of the corneal endothelium in subjects who were implanted with the CyPass Micro-Stent in the COMPASS trial.

Read the detailed description

The COMPASS Trial (TMI-09-01/NCT01085357) was a prospective, randomized, comparative multicenter study to assess the safety and effectiveness of the CyPass Micro-Stent in subjects with primary open angle glaucoma who were undergoing cataract surgery. In the COMPASS Trial, 374 subjects undergoing cataract surgery were randomized to the CyPass group and received the CyPass Micro-Stent, whereas 131 subjects underwent cataract surgery alone. All subjects were to be followed for 2 years postoperatively. Four hundred eighty (480) subjects completed this study.

The COMPASS XT Trial (TMI-09-01E/GLD122b-C001/NCT02700984) was designed to collect safety data beyond 24 months postoperatively for subjects who completed the COMPASS Trial. In COMPASS-XT, clinical data was collected at 36 months, 48 months, and 60 months postoperatively for a total of 5-year follow-up across the 2 studies.

In this trial, COMPASS XXT, clinical data will be collected annually for the subjects who were implanted with the CyPass Micro-Stent in the COMPASS TRIAL until the subject reaches 10 years post-CyPass implantation. For some subjects, the first visit will be at or after 10 years post-CyPass implantation, and therefore the first visit may coincide with the Exit visit.

Being tested
CyPass Micro-Stent, Cataract Surgery
Medical subject headings
Glaucoma, Open-Angle, Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CyPass Micro-StentDevice

    Also called CyPass® Micro-Stent, Model 241-S

    The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.

  • Cataract SurgeryProcedure or surgery

    Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.

Study groups in NCT04629521
Study groupRoleWhat they receive
Cataract Surgery + CyPassExperimentalCyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
Receives: Device: CyPass Micro-Stent; Procedure: Cataract Surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Eyes With Sight-threatening Adverse Events (AEs)

    An adverse event was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device (test product). This analysis was performed using data from visits in the COMPASS XXT study and includes sight-threatening adverse events as specified in the protocol. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) to Month 120 (Year 10) postoperative

  2. Percentage of Eyes With Ocular Adverse Events

    An adverse event was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device (test product). This analysis was performed using data from visits in the COMPASS XXT study and includes ocular events other than sight-threatening adverse events. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) to Month 120 (Year 10) postoperative

  3. Central Endothelial Cell Density (ECD) Reported by Mean and Standard Deviation

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  4. Central Endothelial Cell Density (ECD) Reported by Mean and 95 Percent Confidence Interval

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  5. Central Endothelial Cell Density (ECD) Reported by Percentile - Month 96 (Year 8)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) postoperative

  6. Central Endothelial Cell Density (ECD) Reported by Percentile - Month 108 (Year 9)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 108 (Year 9) postoperative

  7. Central Endothelial Cell Density (ECD) Reported by Percentile - Month 120 (Year 10)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 120 (Year 10) postoperative

  8. Peripheral (Nasal) Endothelial Cell Density (ECD) Reported by Mean and Standard Deviation

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  9. Peripheral (Nasal) Endothelial Cell Density (ECD) Reported by Mean and 95 Percent Confidence Interval

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  10. Peripheral (Nasal) Endothelial Cell Density (ECD) Reported by Percentile - Month 96 (Year 8)

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) postoperative

  11. Peripheral (Nasal) Endothelial Cell Density (ECD) Reported by Percentile - Month 108 (Year 9)

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 108 (Year 9) postoperative

  12. Peripheral (Nasal) Endothelial Cell Density (ECD) Reported by Percentile - Month 120 (Year 10)

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 120 (Year 10) postoperative

  13. Central Endothelial Cell Coefficient of Variation (CECCV) Reported by Mean and Standard Deviation

    The CECCV is a measurement used in assessing the variability and quantifying the degree of variation in endothelial cell size within the central cornea. The CECCV measurements were obtained using specular microscopy from endothelial cells within the central region of the cornea. A higher CECCV suggests greater variability in endothelial cell size within the central cornea and may suggest underlying endothelial cell pathology, such as stress, aging, or certain corneal diseases (e.g. Fuch's endothelial dystrophy). A lower CECCV indicates more uniform cell size distribution, which is typically associated with a healthier endothelial function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  14. Central Endothelial Cell Coefficient of Variation (CECCV) Reported by Percentile - Month 96 (Year 8)

    The CECCV is a measurement used in assessing the variability and quantifying the degree of variation in endothelial cell size within the central cornea. The CECCV measurements were obtained using specular microscopy from endothelial cells within the central region of the cornea. A higher CECCV suggests greater variability in endothelial cell size within the central cornea and may suggest underlying endothelial cell pathology, such as stress, aging, or certain corneal diseases (e.g. Fuch's endothelial dystrophy). A lower CECCV indicates more uniform cell size distribution, which is typically associated with a healthier endothelial function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) postoperative

  15. Central Endothelial Cell Coefficient of Variation (CECCV) Reported by Percentile - Month 108 (Year 9)

    The CECCV is a measurement used in assessing the variability and quantifying the degree of variation in endothelial cell size within the central cornea. The CECCV measurements were obtained using specular microscopy from endothelial cells within the central region of the cornea. A higher CECCV suggests greater variability in endothelial cell size within the central cornea and may suggest underlying endothelial cell pathology, such as stress, aging, or certain corneal diseases (e.g. Fuch's endothelial dystrophy). A lower CECCV indicates more uniform cell size distribution, which is typically associated with a healthier endothelial function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 108 (Year 9) postoperative

  16. Central Endothelial Cell Coefficient of Variation (CECCV) Reported by Percentile - Month 120 (Year 10)

    The CECCV is a measurement used in assessing the variability and quantifying the degree of variation in endothelial cell size within the central cornea. The CECCV measurements were obtained using specular microscopy from endothelial cells within the central region of the cornea. A higher CECCV suggests greater variability in endothelial cell size within the central cornea and may suggest underlying endothelial cell pathology, such as stress, aging, or certain corneal diseases (e.g. Fuch's endothelial dystrophy). A lower CECCV indicates more uniform cell size distribution, which is typically associated with a healthier endothelial function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 120 (Year 10) postoperative

  17. Central Endothelial Hexagonality (CEH) Reported by Mean and Standard Deviation

    The CEH is a measurement used in assessing the regularity of endothelial cell shape within the central cornea. It provides insights into the structural integrity of the corneal endothelium, aiding in the evaluation of corneal health and diagnosis of endothelial cell-related pathologies. The CEH measurement was obtained using specular microscopy, a non-invasive imaging technique that assesses the regularity of endothelial cell shape within the central cornea. A normal cornea is of hexagonal shape. A higher CEH indicates a greater proportion of endothelial cells with a hexagonal shape, which is associated with a more regular and healthier endothelial cell morphology. A lower CEH suggests decreased hexagonality and may indicate abnormalities in endothelial cell structure or function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  18. Central Endothelial Hexagonality (CEH) Reported by Percentile - Month 96 (Year 8)

    The CEH is a measurement used in assessing the regularity of endothelial cell shape within the central cornea. It provides insights into the structural integrity of the corneal endothelium, aiding in the evaluation of corneal health and diagnosis of endothelial cell-related pathologies. The CEH measurement was obtained using specular microscopy, a non-invasive imaging technique that assesses the regularity of endothelial cell shape within the central cornea. A normal cornea is of hexagonal shape. A higher CEH indicates a greater proportion of endothelial cells with a hexagonal shape, which is associated with a more regular and healthier endothelial cell morphology. A lower CEH suggests decreased hexagonality and may indicate abnormalities in endothelial cell structure or function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) postoperative

  19. Central Endothelial Hexagonality (CEH) Reported by Percentile - Month 108 (Year 9)

    The CEH is a measurement used in assessing the regularity of endothelial cell shape within the central cornea. It provides insights into the structural integrity of the corneal endothelium, aiding in the evaluation of corneal health and diagnosis of endothelial cell-related pathologies. The CEH measurement was obtained using specular microscopy, a non-invasive imaging technique that assesses the regularity of endothelial cell shape within the central cornea. A normal cornea is of hexagonal shape. A higher CEH indicates a greater proportion of endothelial cells with a hexagonal shape, which is associated with a more regular and healthier endothelial cell morphology. A lower CEH suggests decreased hexagonality and may indicate abnormalities in endothelial cell structure or function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 108 (Year 9) postoperative

  20. Central Endothelial Hexagonality Reported by Percentile - Month 120 (Year 10)

    The CEH is a measurement used in assessing the regularity of endothelial cell shape within the central cornea. It provides insights into the structural integrity of the corneal endothelium, aiding in the evaluation of corneal health and diagnosis of endothelial cell-related pathologies. The CEH measurement was obtained using specular microscopy, a non-invasive imaging technique that assesses the regularity of endothelial cell shape within the central cornea. A normal cornea is of hexagonal shape. A higher CEH indicates a greater proportion of endothelial cells with a hexagonal shape, which is associated with a more regular and healthier endothelial cell morphology. A lower CEH suggests decreased hexagonality and may indicate abnormalities in endothelial cell structure or function. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 120 (Year 10) postoperative

  21. Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Mean and Standard Deviation

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative change value indicates a lessening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  22. Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Mean and 95 Percent Confidence Interval

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative change value indicates a lessening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  23. Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Percentile - Month 96 (Year 8)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative change value indicates a lessening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8) postoperative

  24. Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Percentile - Month 108 (Year 9)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative change value indicates a lessening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 108 (Year 9) postoperative

  25. Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Percentile - Month 120 (Year 10)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative change value indicates a lessening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 120 (Year 10) postoperative

  26. Percent Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Mean and Standard Deviation

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative percent change value indicates a worsening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  27. Percent Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Mean and 95 Percent Confidence Interval

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative percent change value indicates a worsening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  28. Percent Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Percentile - Month 96 (Year 8)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative percent change value indicates a worsening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8) postoperative

  29. Percent Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Percentile - Month 108 (Year 9)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative percent change value indicates a worsening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 108 (Year 9) postoperative

  30. Percent Change in Central Endothelial Cell Density (ECD) From COMPASS Trial Baseline Visit Reported by Percentile - Month 120 (Year 10)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A negative percent change value indicates a worsening of corneal health and function. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 120 (Year 10) postoperative

  31. Percentage of Eyes According to Central Endothelial Cell Density (ECD) <1000 Cells Per Millimeter Squared

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS, COMPASS XT, and COMPASS XXT studies. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 3, Month 6, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  32. Percentage of Eyes According to Central Endothelial Cell Density (ECD) <500 Cells Per Millimeter Squared

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS, COMPASS XT, and COMPASS XXT studies. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 3, Month 6, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  33. Percentage of Eyes According to Central Endothelial Cell Loss (ECL) Greater Than 30 Percent From Baseline

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. This measurement helps in monitoring the progression of corneal diseases, particularly in conditions where there is a gradual loss of endothelial cells leading to corneal edema and vision loss. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of the corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS, COMPASS XT, and COMPASS XXT studies. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 3, Month 6, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  34. Percentage of Eyes According to Peripheral Endothelial Cell Density (ECD) <1000 Cells Per Millimeter Squared

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  35. Percentage of Eyes According to Peripheral Endothelial Cell Density (ECD) <500 Cells Per Millimeter Squared

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. This measurement is important for detecting peripheral corneal diseases, monitoring progression of corneal diseases, assessing the impact of contact lens wear, and ensuring optimal surgical planning (i.e., corneal transplantation). Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  36. Annualized Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and Standard Deviation

    The annualized rate of change in central ECD is used to quantify the rate at which the central ECD changes over time. The annualized rate of change in central ECD is determined by dividing the change in ECD by the duration of observation (in years). A positive annualized rate of change indicates an increase in central ECD over time, suggesting a favorable outcome or the effectiveness of interventions aimed at preserving endothelial cell density. A negative annualized rate of change signifies a decrease in central ECD, which may indicate endothelial cell loss due to factors such as aging, disease progression, or the surgical interventions. This analysis was performed using data from the COMPASS study, the COMPASS XT study, and the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  37. Annualized Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and 95 Percent Confidence Interval

    The annualized rate of change in central ECD is used to quantify the rate at which the central ECD changes over time. The annualized rate of change in central ECD is determined by dividing the change in ECD by the duration of observation (in years). A positive annualized rate of change indicates an increase in central ECD over time, suggesting a favorable outcome or the effectiveness of interventions aimed at preserving endothelial cell density. A negative annualized rate of change signifies a decrease in central ECD, which may indicate endothelial cell loss due to factors such as aging, disease progression, or the surgical interventions. This analysis was performed using data from the COMPASS study, the COMPASS XT study, and the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  38. Annualized Percent Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and Standard Deviation

    The annualized rate of change in central ECD is used to quantify the rate at which the central ECD changes over time. The annualized rate of change in central ECD is determined by dividing the change in ECD by the duration of observation (in years). A positive percent change per year indicates an increase in central ECD over time, suggesting a favorable outcome or the effectiveness of interventions aimed at preserving endothelial cell density. A negative percent change per year may indicate endothelial cell loss due to factors such as aging, disease progression, or the surgical interventions. This analysis was performed using data from the COMPASS study, the COMPASS XT study, and the COMPASS XXT study. Central ECD was measured in cells per millimeter squared. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  39. Annualized Percent Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and 95 Percent Confidence Interval

    The annualized rate of change in central ECD is used to quantify the rate at which the central ECD changes over time. The annualized rate of change in central ECD is determined by dividing the change in ECD by the duration of observation (in years). A positive percent change per year indicates an increase in central ECD over time, suggesting a favorable outcome or the effectiveness of interventions aimed at preserving endothelial cell density. A negative percent change per year may indicate endothelial cell loss due to factors such as aging, disease progression, or the surgical interventions. This analysis was performed using data from the COMPASS study, the COMPASS XT study, and the COMPASS XXT study. Central ECD was measured in cells per millimeter squared. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  40. Number of Corneal Sequelae Events Associated With Endothelial Cell Loss (ECL)

    Corneal sequelae are occurrences of complications related to ECL in the cornea and may include corneal edema, decreased visual acuity, corneal decompensation, bullous keratopathy, etc. Corneal sequelae were quantified by counting the instances where patients experienced complications attributable to endothelial cell loss. A higher number of corneal sequelae events may indicate rapid disease progression or inadequate management of conditions leading to endothelial cell loss. A lower number of corneal sequelae events may indicate a favorable response to treatment and successful disease treatment or treatment stabilization. This analysis was performed using data from the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  41. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Mean and Standard Deviation

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS study, the COMPASS XT study, and the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 3, Month 6, Month 12 (Year 1), Month 24 (Year 2), Month 36 (Year 3), Month 48 (Year 4), Month 60 (Year 5), Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10)

  42. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 3

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 3 postoperative

  43. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 6

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 6 postoperative

  44. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 12 (Year 1)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 12 (Year 1) postoperative

  45. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 24 (Year 2)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 24 (Year 2) postoperative

  46. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 36 (Year 3)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS XT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 36 (Year 3) postoperative

  47. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 48 (Year 4)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS XT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 48 (Year 4) postoperative

  48. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 60 (Year 5)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS XT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 60 (Year 5) postoperative

  49. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 96 (Year 8)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) postoperative

  50. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 108 (Year 9)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 108 (Year 9) postoperative

  51. Central Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 120 (Year 10)

    Central ECD refers to the number of endothelial cells present per square millimeter in the central cornea. Central ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of corneal endothelial cells in the central cornea. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed using data from the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 120 (Year 10) postoperative

  52. Peripheral Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Mean and Standard Deviation

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  53. Peripheral Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 96 (Year 8)

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) postoperative

  54. Peripheral Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 108 (Year 9)

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 108 (Year 9) postoperative

  55. Peripheral Endothelial Cell Density (ECD) by Number of Rings Observed at the Visit Reported by Percentile - Month 120 (Year 10)

    Peripheral ECD refers to the number of endothelial cells present per square millimeter in the peripheral cornea. Peripheral ECD was assessed using specular microscopy, a non-invasive imaging technique that allows for visualization and quantification of endothelial cells. A normal ECD in adults typically ranges between 2500 to 3000 cells per square millimeter, although this can vary depending on age and individual variation. A higher value indicates better corneal health and function. A lower value suggests potential endothelial dysfunction or damage. This analysis was performed data from visits in the COMPASS XXT study. Only data for subjects with rings visible on the CyPass MicroStent device and ECD data is presented. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 120 (Year 10) postoperative

  56. Number of Secondary Surgical Intervention (SSI) Events to Modify the Device Position (eg, Repositioning, Trimming, Explantation)

    SSI events are additional surgical procedures performed after the initial placement of the CyPass micro-stent device to adjust its position or address issues related to its placement. SSI were noted through adverse event reporting, clinical evaluation, comprehensive documentation of outcome assessment and data analysis. A higher number of SSI events may indicate challenges or complications related to the initial placement of the CyPass device, technical difficulties during the initial surgery, device-related issues, or patient-specific factors contributing to the need for additional interventions. A lower number of SSI events may suggest that the initial device placement was successful and well-tolerated, with fewer complications or the need for adjustments. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) to Month 120 (Year 10) postoperative

  57. Percentage of Eyes With CyPass Micro-Stent Movement and/or Malposition

    CyPass micro-stent movement and/or malposition refers to issues related to the displacement or improper positioning of the CyPass Micro-Stent in the eye's drainage angle. The investigator qualitatively and subjectively assessed the position of the device by counting the visible number of rings of the device during a gonioscopic exam, which used a specialized lens to visually assess the position and stability of the CyPass device. Movement and/or malposition may suggest a greater risk of complications or inadequate treatment of glaucoma. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) to Month 120 (Year 10) postoperative

  58. Number of Corneal Adverse Events Caused by CyPass MicroStent

    A corneal adverse event is an undesirable occurrence related to the cornea, such as inflammation, edema, epithelial defects, or other complications. The number of corneal adverse events caused by the CyPass Micro-Stent was assessed from patient reporting, clinical observation and documentation during patients' follow-up visits. This analysis was performed using data from visits in the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) to Month 120 (Year 10) postoperative

  59. Number of Events of Best Corrected Visual Acuity (BCVA) Loss of 10 Letters or More

    Visual acuity was measured with correction in place using letter charts. BCVA [synonymous with Best Corrected Distance Visual Acuity (BCDVA)] at each visit was compared to the participant's best achieved BCVA recorded throughout the 10-year period after CyPass implantation. This analysis was performed using data from the COMPASS study, the COMPASS XT study, and the COMPASS XXT study. No hypothesis testing was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Month 96 (Year 8) to Month 120 (Year 10) postoperative

  60. Change in Visual Field Mean Deviation From COMPASS Trial Screening Visit Reported by Mean and Standard Deviation

    Visual field mean deviation is a measure used in visual field testing to assess the overall sensitivity of a patient's vision compared to a standardized norm. The Humphrey automated perimeter with the 24-2 Swedish Interactive Thresholding Algorithm (SITA) standard testing method was used. Deviations were recorded in decibels. Normal deviation values are typically within 0 to -2 decibels (dB). A more negative number indicates decreased sensitivity and worsening of the overall visual field. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Screening (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  61. Percentage of Eyes With Change in Visual Field Mean Deviation From COMPASS Trial Screening Visit Reported Categorically - 2 Decibel (dB)

    Visual field mean deviation is a measure used in visual field testing to assess the overall sensitivity of a patient's vision compared to a standardized norm. The Humphrey automated perimeter with the 24-2 SITA standard testing method was used. Deviations were recorded in decibels. Normal deviation values are typically within 0 to -2 decibels (dB). A more negative number indicates decreased sensitivity and worsening of the overall visual field. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Screening (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  62. Change in Central Corneal Thickness (CCT) From COMPASS Trial Baseline Visit Reported by Mean and Standard Deviation

    CCT is a measurement of the thickness of the cornea at its center and is assessed using a procedure called corneal pachymetry. A high CCT (thick cornea) indicates a central cornea thicker than average and may be associated with conditions such as corneal edema, Fuchs' dystrophy, or ocular hypertension. A low CCT (thin cornea) indicates a central cornea thinner than average and may be a risk factor for developing conditions such as glaucoma. A negative change value indicates a decrease in corneal thickness. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

  63. Change in Central Corneal Thickness (CCT) From COMPASS Trial Baseline Visit Reported by Mean and 95 Percent Confidence Interval

    CCT is a measurement of the thickness of the cornea at its center and is assessed using a procedure called corneal pachymetry. A high CCT (thick cornea) indicates a central cornea thicker than average and may be associated with conditions such as corneal edema, Fuchs' dystrophy, or ocular hypertension. A low CCT (thin cornea) indicates a central cornea thinner than average and may be a risk factor for developing conditions such as glaucoma. A negative change value indicates a decrease in corneal thickness. This analysis was performed using data from the COMPASS study and data from the COMPASS XXT study. No hypothesis was prespecified for this outcome measure. One eye (study eye) contributed data to this analysis.

    Measured: Baseline (COMPASS Study) preoperative, Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Nov 2020
  2. Study start21 Dec 2020
  3. Primary completion5 Apr 2023
  4. Study completion5 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
54 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04629521
Sponsor's protocol ID
GLD122-P004
Acronym
COMPASS XXT
Status last verified
Apr 2024
First submitted
10 Nov 2020
Last updated
26 Apr 2024
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing CyPass Micro-Stent and Cataract Surgery in people with Primary Open Angle Glaucoma and Cataract, run by Alcon Research at 12 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Apr 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Eyes With Sight-threatening Adverse Events (AEs) (time frame: Month 96 (Year 8) to Month 120 (Year 10) postoperative). The study lists 63 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in